<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39554516</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1715-1635</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2024</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC</Title><ISOAbbreviation>Can Pharm J (Ott)</ISOAbbreviation></Journal><ArticleTitle>Opportunities and challenges associated with the launch of nirmatrelvir/ritonavir (Paxlovid) in British Columbia during the COVID-19 pandemic: A qualitative study to explore community pharmacists' perspectives.</ArticleTitle><Pagination><StartPage>17151635241288577</StartPage><MedlinePgn>17151635241288577</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17151635241288577</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/17151635241288577</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In February 2022, a novel antiviral for the treatment of COVID-19, nirmatrelvir/ritonavir (Paxlovid), was approved by Health Canada and made available to patients in British Columbia (BC). BC community pharmacists did not prescribe nirmatrelvir/ritonavir, but dispensing involved a detailed assessment with close attention to drug-drug interactions and patient monitoring. As the nirmatrelvir/ritonavir service was unique in BC, and not all pharmacists participated in the program, it is important to evaluate the perspectives of all the pharmacists who were affected so that lessons learned from the program can inform future pandemic planning and government initiatives.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A qualitative research study using key informant semistructured interviews was conducted. Community pharmacists with varying degrees of experience with nirmatrelvir/ritonavir were recruited using multiple methods of recruitment through e-mail and fax invitations and social media posts. Open-ended questions explored pharmacists' experiences with the nirmatrelvir/ritonavir program, including barriers and facilitators to dispensing it, and recommendations for future pharmacy initiatives.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Forty-three community pharmacists participated in the study. Most participants were between the ages of 30 and 39 years and had practiced for less than 10 years. Thematic analysis yielded 36 codes that were organized into 3 overarching themes related to the following: learning; in-process experiences, supports, difficulties; and perceptions about the expanded scope of practice.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">The following strategies may be helpful to consider including in future initiatives: preprinted forms, a hotline for peer support, slower rollouts, a single source for communicating changes, a patient portal, addressing the divisions between dispensary and clinical work, and having specialized positions to support future rollouts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Lessons learned from the nirmatrelvir/ritonavir service included a slower approach to program initiation with additional training opportunities and more streamlined prescription options. Pharmacists also wished for better communication support and involvement in the planning of future initiatives.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dahri</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5653-6056</Identifier><AffiliationInfo><Affiliation>Vancouver General Hospital, Vancouver, BC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinclair Formerly MacNeil</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Education, University of British Columbia, Vancouver, BC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piszczek</LastName><ForeName>Jolanta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>BC COVID Therapeutics Committee, Vancouver, BC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilbur</LastName><ForeName>Kerry</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5936-4429</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Bryce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>BC Pharmacy Association, Vancouver, BC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>I Fan</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>BC Ministry of Health, Government of Canada, Victoria, BC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Fawziah</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1266-1901</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can Pharm J (Ott)</MedlineTA><NlmUniqueID>101257110</NlmUniqueID><ISSNLinking>1715-1635</ISSNLinking></MedlineJournalInfo><CoiStatement>None of the authors report a conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39554516</ArticleId><ArticleId IdType="pmc">PMC11565502</ArticleId><ArticleId IdType="doi">10.1177/17151635241288577</ArticleId><ArticleId IdType="pii">10.1177_17151635241288577</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Health Canada. Paxlovid™ (nirmatrelvir/ritonavir). 2022. Available: https://covid-vaccine.canada.ca/paxlovid/product-details (accessed Nov. 27, 2022).</Citation></Reference><Reference><Citation>
Paxlovid™. Product monograph. 2022. Available: https://covid-vaccine.canada.ca/info/pdf/paxlovid-pm-en.pdf (accessed Nov. 27, 2022).</Citation></Reference><Reference><Citation>
BC Ministry of Health. Nirmatrelvir/ritonavir (Paxlovid™) - Plan Z (or ZE). 2022. Available: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/limited-coverage-drug-program/plan-z-nirmatrelvir-ritonavir-paxlovid (accessed Nov. 29, 2022).</Citation></Reference><Reference><Citation>Loos NHC, Beijnen JH, Schinkel AH. The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism? Int J Mol Sci 2022;23(17):9866. doi:10.3390/ijms23179866</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23179866</ArticleId><ArticleId IdType="pmc">PMC9456214</ArticleId><ArticleId IdType="pubmed">36077262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al.. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022;386(15):1397-408. doi:10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>
Public Health Agency of Canada. Nirmatrelvir/ritonavir implementation in Canada summary evaluation report: January to August 2022. Ottawa (Canada): Public Health Agency of Canada; February
2023:1-36. Available: https://publications.gc.ca/collections/collection_2023/aspc-phac/HP40-331-2023-eng.pdf (accessed Nov. 5, 2023).</Citation></Reference><Reference><Citation>
BC Centre for Disease Control. Clinical practice guide for the use of therapeutics in mild-moderate COVID-19. 2023. Available: http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/ClinicalPracticeGuide_Therapeutics_MildModerateCOVID.pdf (accessed Nov. 6, 2023).</Citation></Reference><Reference><Citation>Jebara T, Cunningham S, MacLure K, Awaisu A. Stakeholders’ views and experiences of pharmacist prescribing: a systematic review. Br J Clin Pharmacol 2018;84:1883-905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6089831</ArticleId><ArticleId IdType="pubmed">29873098</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19(6):349-57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17872937</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles MB, Huberman AM, Saldaña J. Qualitative data analysis: a methods sourcebook. 4th ed. London (UK): Sage; 2020.</Citation></Reference><Reference><Citation>Tavory I, Timmermans S. Theory construction in qualitative research: from grounded theory to abductive analysis. Sociol Theory 2014;30(3):167-86.</Citation></Reference><Reference><Citation>
DeClerq K.
Rate of dispensing Paxlovid up 130 per cent since Ontario pharmacists were allowed to prescribe. CTV News Toronto. 2023. Available: https://toronto.ctvnews.ca/rate-of-dispensing-paxlovid-up-130-per-cent-since-ontario-pharmacists-were-allowed-to-prescribe-1.6218542 (accessed Jun. 7, 2024).</Citation></Reference><Reference><Citation>
Kaiser L. P.E.I.
pharmacists can now prescribe COVID-19 Paxlovid treatment. CTV News Atlantic. 2023. Available: https://atlantic.ctvnews.ca/p-e-i-pharmacists-can-now-prescribe-covid-19-paxlovid-treatment-1.6227992 (accessed Jun. 7, 2024).</Citation></Reference><Reference><Citation>Kieck D, Mahalick L, Vo TT. Medication-related problems identified and addressed by pharmacists dispensing COVID-19 antivirals at a community pharmacy. Pharmacy (Basel) 2023;11(3):87. doi:10.3390/pharmacy11030087</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmacy11030087</ArticleId><ArticleId IdType="pmc">PMC10204433</ArticleId><ArticleId IdType="pubmed">37218969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CT, Ong SY, Lim XJ, Chew LS, Rajan P. Managing nirmatrelvir/ritonavir during COVID-19: pharmacists’ experiences from the Perak state of Malaysia. J Pharm Policy Pract 2022;15(1):70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9589596</ArticleId><ArticleId IdType="pubmed">36274169</ArticleId></ArticleIdList></Reference><Reference><Citation>Famularo DE, Koloski J, Marathe J, et al.. Pharmacist-driven assessment and prescribing of COVID-19 therapeutics: a large, tertiary academic medical center’s experience. Am J Health Syst Pharm 2022;79(21):1889-93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384582</ArticleId><ArticleId IdType="pubmed">35917116</ArticleId></ArticleIdList></Reference><Reference><Citation>Portman DB, Scolese CJ. Facilitating oral COVID-19 therapy utilization through a pharmacy consult service. J Am Pharm Assoc 2023;63(4):1237-41. doi:10.1016/j.japh.2023.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.japh.2023.04.010</ArticleId><ArticleId IdType="pmc">PMC10116126</ArticleId><ArticleId IdType="pubmed">37084811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kravetz JD, Tarabar AF, Dalton RJ, Kotansky B, Curtin RN. Implementation of a standardized process for outpatient COVID-19 treatments at a Veterans Affairs medical center. J Am Pharm Assoc 2022;62(6):1880-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9233347</ArticleId><ArticleId IdType="pubmed">35961939</ArticleId></ArticleIdList></Reference><Reference><Citation>Millstein JH, Asch DA, Hamilton K, Adusumalli S, Kasbekar N, Ahya V, Al-Ramahi N. Decision support and centralized pharmacy consultation for nirmatrelvir-ritonavir prescribing in an academic health system-a model to promote drug access and reduce provider burden. J Gen Intern Med 2022;37(15):4028-31. doi:10.1007/s11606-022-07752-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07752-6</ArticleId><ArticleId IdType="pmc">PMC9362507</ArticleId><ArticleId IdType="pubmed">35922709</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>